RDNT vs. FTRE, GH, VCYT, VRDN, FLGT, CSTL, CDNA, BDSX, BNR, and PSNL
Should you be buying RadNet stock or one of its competitors? The main competitors of RadNet include Fortrea (FTRE), Guardant Health (GH), Veracyte (VCYT), Viridian Therapeutics (VRDN), Fulgent Genetics (FLGT), Castle Biosciences (CSTL), CareDx (CDNA), Biodesix (BDSX), Burning Rock Biotech (BNR), and Personalis (PSNL). These companies are all part of the "medical laboratories" industry.
Fortrea (NASDAQ:FTRE) and RadNet (NASDAQ:RDNT) are both mid-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, risk, earnings, dividends, valuation, analyst recommendations, community ranking, institutional ownership and media sentiment.
RadNet has lower revenue, but higher earnings than Fortrea.
RadNet received 335 more outperform votes than Fortrea when rated by MarketBeat users. Likewise, 65.76% of users gave RadNet an outperform vote while only 38.46% of users gave Fortrea an outperform vote.
77.9% of RadNet shares are owned by institutional investors. 0.1% of Fortrea shares are owned by company insiders. Comparatively, 4.4% of RadNet shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
RadNet has a net margin of 1.28% compared to RadNet's net margin of 0.00%. Fortrea's return on equity of 5.05% beat RadNet's return on equity.
In the previous week, RadNet had 12 more articles in the media than Fortrea. MarketBeat recorded 23 mentions for RadNet and 11 mentions for Fortrea. RadNet's average media sentiment score of 1.20 beat Fortrea's score of 0.66 indicating that Fortrea is being referred to more favorably in the media.
Fortrea presently has a consensus price target of $37.29, indicating a potential upside of 12.88%. RadNet has a consensus price target of $55.25, indicating a potential upside of 0.00%. Given RadNet's higher possible upside, equities research analysts clearly believe Fortrea is more favorable than RadNet.
Summary
RadNet beats Fortrea on 11 of the 15 factors compared between the two stocks.
Get RadNet News Delivered to You Automatically
Sign up to receive the latest news and ratings for RDNT and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding RDNT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
